For the month ended 30 April 2026, Brii Biosciences Limited reported a net increase of 47,409 ordinary shares, lifting its outstanding share count (excluding treasury stock) to 721.81 million. Treasury shares were unchanged at 12.72 million, keeping total issued shares at 734.53 million.

The additional shares stemmed entirely from the company’s share-based incentive programmes: • Post-IPO Share Award Scheme: 38,145 shares issued. • 2023 Share Award Scheme: 9,264 shares issued.

No new shares were created through option exercises, warrants or convertibles during the month. As a result, total funds raised from option exercises were HKD 0.

Option pool movements were limited to lapses: • Pre-IPO Share Incentive Scheme options outstanding fell by 0.30 million to 5.55 million. • Post-IPO Share Option Scheme options outstanding declined by 0.52 million to 9.92 million. • 2023 Share Option Scheme options outstanding dropped by 0.26 million to 24.97 million.

Authorised share capital remained unchanged at 1.20 billion ordinary shares with a nominal value of USD 0.000005 each, equivalent to USD 6,000.

Brii Biosciences confirmed that its public float comfortably meets the Hong Kong Main Board’s minimum 25 % requirement as of 30 April 2026, and all share issuances complied with applicable listing rules and legal obligations.